Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.

PharmacoEconomics - open·2026
Same author

The management of NSAID-ERD patients in the current treatment landscape: aspirin desensitization, biologics, both, or neither?

The journal of allergy and clinical immunology. In practice·2026
Same author

Rescue Inhaler Overuse in Severe Asthma: A Real-World Study of Short-Acting β<sub>2</sub>-Agonist and Short-Acting Muscarinic Antagonist Use.

Biomedicines·2026
Same author

EAACI Guidelines on Environmental Science for Allergy and Asthma-Evidence-Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy.

Allergy·2026
Same author

Real-World Effectiveness of Tezepelumab Across T2 and Non-T2 Severe Asthma Phenotypes: A Multicenter Spanish Cohort Study.

Archivos de bronconeumologia·2026
Same author

A Multi-Compartment Cytological Approach to Severe Asthma Phenotyping: The BRISA Study (Biomedical Research in Severe Asthma).

Journal of asthma and allergy·2026

Related Experiment Video

Updated: May 22, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Emerging drugs for asthma.

Santiago Quirce1, Irina Bobolea, Pilar Barranco

  • 1Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. squirce.hulp@salud.madrid.org

Expert Opinion on Emerging Drugs
|May 22, 2012
PubMed
Summary
This summary is machine-generated.

Current asthma treatments manage symptoms but do not cure the disease, leaving many patients with uncontrolled asthma. New biologic therapies and individualized treatment approaches are emerging to address this unmet need.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Related Experiment Videos

Last Updated: May 22, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Immunology
  • Pharmacology

Background:

  • Current asthma pharmacotherapies alleviate bronchospasm and inflammation but do not provide a cure, with symptom recurrence upon cessation.
  • Despite established guidelines and available treatments, achieving optimal asthma control remains a significant challenge for a substantial patient population.
  • The unmet need for effective asthma management underscores the necessity for novel therapeutic strategies.

Purpose of the Study:

  • To review advancements in asthma treatment, focusing on novel therapies for difficult-to-control asthma.
  • To highlight the potential of biologic therapies, particularly monoclonal antibodies, in managing severe asthma phenotypes.
  • To discuss the development of new combination inhaler therapies.

Main Methods:

  • Review of current literature on asthma pathophysiology and treatment strategies.
  • Identification of characteristic features distinguishing severe from mild-to-moderate asthma.
  • Analysis of emerging therapeutic options, including biologics and combination inhalers.

Main Results:

  • Significant progress has been made in characterizing severe asthma, paving the way for personalized treatment approaches.
  • Biologic therapies, especially monoclonal antibodies, represent a promising frontier in managing specific asthma phenotypes.
  • Novel once-daily inhaled corticosteroid and long-acting beta-agonist combinations are under development.

Conclusions:

  • Asthma is a heterogeneous condition with diverse underlying pathophysiologies and distinct phenotypes.
  • Effective asthma management requires identifying individual patient profiles and targeting specific inflammatory pathways.
  • Cytokine involvement in various asthma phenotypes presents both a challenge and an opportunity for targeted therapeutic interventions.